Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Product candidates
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
22 Mar 2021 - 25 Mar 2021
BioEurope Spring – virtual
17 Apr 2021 - 22 Apr 2021
2021 AAN Annual Meeting, virtual
06 Apr 2021 - 09 Apr 2021
Cell & Gene Meeting on the Mediterranean, virtual
25 Mar 2021
Ophthalmology Future Forums – Asian Retina Virtual Forum
15 February 2021
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs
22 Feb 2021 - 25 Feb 2021
4th Annual Gene Therapy for Rare Disorders – virtual
18 Feb 2021
OIS Gene Therapy Innovation Showcase – virtual
06 Feb 2021 - 07 Feb 2021
44th Annual Macula Society Meeting – Virtual
04 February 2021
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non Human Primates
13 January 2021
GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®
View previous 9 articles
1
2
3
4
5
6
7
8
9
10
11
12
…
16
View next 9 articles
Go back to the page of the page